Introduction
Acute promyelocytic leukemia (APL) represents a well-defined class of human myeloid leukemia 1 characterized by the t(15;17) chromosomal translocation. [2] [3] [4] The chimeric protein, PML-RAR␣, [5] [6] [7] is generally considered as the likely cause of the maturation defect, due to altered function of both PML and RAR␣ genes. 8, 9 That retinoic acid (RA) induces APL cell maturation, both in vivo [10] [11] [12] and in vitro, 13 strongly suggests that retinoid signalling triggers a cascade of transcriptional regulations necessary to embark the cells on a maturation process. Those cascades of gene regulation not only induce cell maturation for the benefit of the patient, but are likely responsible for the side-effects associated with retinoid treatment (retinoid syndrome). With this therapy, a tumor cell is restored into a physiological program (maturation therapy) by using cellular signaling. Obviously, there is considerable interest in extending this strategy to other malignancies. [14] [15] [16] The APL cell line NB4, 17 with both retinoid-sensitive and resistant subclones 18, 19 all derived from the same APL patient, constitutes an appropriate cell system for in vitro analysis of gene regulation and phenotypic changes associated with granulocytic maturation. Initially, it has been assumed that PML-RAR␣ participates in leukemia cell transformation and blocks myeloid differentiation by exerting a 'dominant negative' activity on RAR␣-dependent mechanisms. 5, 6, 20 No consistent conclusion as to whether APL resulted from disruption of RAR␣ signaling emerged from these studies. Other studies, in contrast, have favored the hypothesis that PML functions (cell cycle regulation, apoptosis) are altered by the presence of PML-RAR␣. [21] [22] [23] [24] [25] According to another model, RXR/PML-RAR␣ heterodimers disrupt nuclear bodies [26] [27] [28] which causes sequestration of RXR␣. 29 Different groups have suggested that PML-RAR␣ has to be targeted to induce cell maturation. This could be obtained by inducing conformational changes of PML-RAR␣ consecutive to the binding of RA, in such a manner that nuclear bodies reform, 27 concomitantly to a release of the sequestrated RXR␣ 28 from these ill-defined nuclear structures. PML-RAR␣ degradation during ATRA treatment may also be involved to overcome the block in myeloid differentiation. 30, 31 However, several findings do not fully support these hypotheses. For instance, nuclear bodies reform late compared to the RXR-dependent transcriptional events supposed to trigger the gene expression necessary to cell maturation. Moreover, ATRA is not sufficient by itself to induce maturation of NB4-R1 cells, 29 and nuclear bodies reformed only if cells are simultaneously treated with RA and cAMP. Also intriguing is the fact that the NB4-R2, a maturation-resistant subclone of NB4 which is defective for PML-RAR␣, exhibits micro-punctuated nuclear bodies. 31 Despite the abundant literature (see a recent review in Ref. 32) , no unifying model has yet emerged, regarding either the mechanism of oncogenesis in APL or the onco-suppressor action of RA in this pathology. The difficulty in understanding the mechanisms of leukemia cell maturation is most probably reflecting the fact that cell maturation, in addition to RA stimulation, also depends on additional cellular signaling. Several lines of evidence strongly suggest that signaling pathways targeting both the nucleus and the plasma membrane participate in NB4 cell maturation. 16, 31, [33] [34] [35] [36] [37] Complementary approaches aimed at a more precise determination of the phenotypic changes occurring during maturation are now used to trace the transcriptional activity downstream from RA stimulation, in both sensitive and resistant cells (cDNA differential display, 38 expressed gene trap or promoter trap. [39] [40] [41] The main advantage of these approaches is that they offer the possibility to appraise even subtle transcriptional modifications occurring in a physiological context. The PCR-based differential display of cDNA 38 is a powerful approach to identify novel genes that are directly or indirectly regulated after RA stimulation. Using this method, several novel genes have been identified during NB4 cell maturation, including RIG-E, 42 RIG-G 43 and JEM-1. 44 It will be important to characterize the common denominator in the expression of these genes: are they a direct target of RA or controlled by distinct signalling? The tissue expression of these genes may prove to be useful markers to characterize intracellular signaling during APL cell maturation and should orient investigations on their functions.
In a recent work, we reported the primary structure of JEM-1 cDNA, its localization on chromosome 1q24, and its ectopic expression. JEM-1 cDNA was ectopically expressed as a basic 45 kDa nuclear protein. 44 In this work, we characterized the expression pattern of JEM-1 mRNA in sensitive and resistant NB4 cells, in other non-APL leukemia cell lines and in solid tumors. This study was also extended to normal fetal and adult tissues.
Materials and methods

Reagents
All-trans retinoic acid (ATRA) was purchased from Sigma (St Louis, MO, USA). 9-cis retinoic acid, TTNPB and LG268 were generous gifts of Dr R Heyman (Ligand Pharmaceutical, CA, USA). Stock solutions (10 −2 M), prepared by dissolving the compounds either in ethanol or DMSO, were stored in the dark at −30°C and routinely used at 1 M.
Cell lines and cell cultures
The human promyelocytic leukemia cell line, NB4, was cultured and treated with ATRA as previously described. 17 The isolation and characterization of the maturation resistant cell line NB4-R1 have been previously reported. 19, 29, 31 Briefly, cultures were initiated by seeding 2 × 10 5 cells per ml of fresh RPMI 1640 medium (Gibco-BRL, Pontoise, France) supplemented with L-glutamine (2 mM), antibiotics and 10% (v/v) fetal calf serum (Boehringer-Mannheim, Germany). Cultures were maintained at 3 to 5 × 10 5 cells per ml by a daily adjustment of the cell concentration, adding fresh culture medium with supplements when necessary. Cells were incubated at 37°C in an air/5% CO 2 atmosphere. Differentiation was evaluated by morphology with May-Grü nwald-Giemsa and by nitroblue tetrazolium (NBT; Sigma) reduction assay. Bone marrow and blood samples from leukemia patients were collected (Department of Internal Medicine, University Hospital, Umea, Sweden) after informed consent of the donors. After Ficoll-Hypaque gradient separation, cells were pelleted for total RNA extraction.
Northern blot analysis
RNA was extracted using a standard protocol 45 followed by CsCl gradient centrifugation for purification. Poly A + RNA was purified on an oligo-dT cellulose column (Boehringer). Fetal and adult tissue expression analyses were carried out using purified Poly A ϩ RNA (5 g per lane), electrophoresced and transferred on Nylon-N membranes (Clontech, Palo Alto, CA, USA). Solid tumor and leukemia cell line derived RNAs were prepared either by Clontech (Multiple Tissue Northern (MTN) blots) or by DSMZ (Braunschweig, Germany). Nylon-N membranes were then hybridized to a 32 P-labeled JEM cDNA fragment. 44 cDNA probes were labelled with a 'random priming' kit (Promega, Madison, WI, USA).
PCR amplification assays for JEM-1 mRNA expression
cDNAs were synthesized by reverse-transcription. One microgram of total RNA was used to synthesize cDNA in a 40 l reaction mixture containing 100 ng random hexamers, 200 U Moloney murine leukemia virus reverse transcriptase (MMLV-RT, Gibco), and 40 U RNasin. All RT reactions were performed at 35°C for 1 h, followed by a 5-min incubation at 95°C. For PCR amplification control, a competitor template was generated within the JEM-1 ORF by using MaeII restriction enzyme to excise the leucine motif (amino acids 179 to 206). After ligation into a pSG5 expression plasmid, the JEM⌬L 179-206 cDNA template was produced and purified. One microliter of each cDNA sample was mixed with 0.1 pg of competitor plasmid DNA and subjected to PCR amplification in a Perkin-Elmer thermocycler (Perkin-Elmer, Norwalk, CT, USA). The sense and anti-sense primers were 5Ј GAGCCCAG-GAGTTCTTCTTCAGCTAG 3Ј and 5Ј TGCATCACGGTTTTG-ACGCTG 3Ј respectively. The PCR reaction was performed in a 50 l mixture containing 80 pmol of each primer at 95°C for 5 min (one cycle); 94°C for 25 s; 55°C for 1.5 min; and 72°C for 3 min (30 cycles) and 5 min (one cycle). To estimate total cDNA loading 1 l of cDNA was subjected to a PCR amplification of a ␤-actin cDNA fragment (217 bp) in a 50 l reaction mixture containing 100 ng sense and anti-sense primers. Primer sequences were as follows: (1) sense: 5Ј AAGA-GAGGCATCCTCACCC 3Ј; (2) antisense: 5Ј TACTTGGCTGG-GGTGTTGAA 3Ј. The PCR parameters were as described above for JEM cDNA amplification.
Results and discussion
JEM-1 mRNA expression in NB4 cell lines in response to retinoids
JEM-1 gene was previously identified by the technique of PCR differential display of cDNA due to a low expression in NB4 cells while it was strongly up-regulated after 48 h of treatment with ATRA. 44 This result was further confirmed by Northern blot analysis using a full-length cDNA probe. Since JEM-1 mRNA up-regulation was concomitant with cell maturation, we investigated whether JEM-1 followed a distinct regulation process in retinoid-responsive and -resistant NB4 cells, and whether this RA-response profile could be extended to the in vivo response of APL bone marrow cells to RA.
NB4 cells were treated for increasing incubation times (from 2 to 96 h) with the RAR␣ agonist TTNPB, the pan-agonists ATRA and 9-cis RA, and the RXR␣ agonist LG268. Cell maturation was evaluated by morphological analysis after MayGrunwald-Giemsa staining (not shown). Total RNA was extracted and analyzed by Northern blot.
JEM-1 expression in NB4 cells stimulated with pan-agonists (ATRA or 9-cis RA) was typically biphasic. JEM-1 up-regulation was already significant after 2 h, and a first peak of JEM-1 mRNA expression was detected after 6 h of incubation, followed by a progressive decrease in JEM-1 mRNA with a nadir at 20-24 h. A second round of induction was then observed with a peak at 72-96 h (Figure 1a) . The second peak of expression being observed concomitantly to cell maturation.
When cells were treated with the synthetic RAR selective analog TTNPB, the time-course of JEM-1 mRNA expression was slightly different (Figure 1b) . Although the response was also biphasic with this drug, the second peak occurred earlier (48 h), after which JEM-1 mRNA levels reached a plateau (when normalized with actin mRNA). This is in line with our observation that terminal maturation of NB4 cells also occurred earlier when cells were triggered by TTNPB (not shown).
RXR␣ selective agonists (eg LG268) failed to induce maturation of NB4 cells (unpublished observation). These compounds also failed to up-regulate JEM-1 mRNA (Figure 1c,  lanes 1 and 2) . Importantly, cAMP signalling (8-CPT-cAMP; 100 M) cooperated with LG268 (1 M) to induce granulocytic cell maturation in immature LG268-primed NB4 cells (not shown). We observed that the induction of NB4 cell maturation by the combined activation of RA and cAMP signaling was correlated with the induction of JEM-1 expression (Figure 1c) . The profile of JEM-1 expression during LG 268 and 8-CPT cAMP treatment (Figure 1c, lanes 3 to 9) exquisitely reproduced the biphasic pattern obtained with RAR␣ agonist triggering (Figure 1b) , featuring a first peak at 6-8 h and a much more pronounced second peak at 48 h. The late decrease of JEM-1 mRNA (lane 9) was associated with terminal maturation and apoptosis immediately afterwards (72 h) in these culture conditions. These data support the notion that (1) ligand-dependent RXR signaling and cAMP-signaling cross-talk is required for maturation of APL cells, while liganddependent RAR␣ signaling is self-sufficient; (2) JEM-1 mRNA expression accompanied NB4 cell maturation, whatever the inducer signal is.
The patterns of JEM expression in NB4 and NB4-R1 cells were interesting to compare. In the two cell lines retinoid treatments (LG 628 in NB4 cells, unpublished; ATRA in NB4-R1 cells, see Ref. 16 ) failed to induce cell maturation, while after a pretreatment with these retinoids the maturation of two cell lines was triggered. We previously reported 44 that ATRA also failed to increase JEM-1 mRNA levels in NB4-R1 cells. The steady state of JEM-1 during ATRA stimulation of NB4-R1 cells illustrated in Figure 2a is confirmation of this result. We next analyzed the effect of a combination of the two inducers, ATRA and cAMP, on RA-primed NB4-R1 cells. The results in Figure 2b show that JEM-1 was up-regulated when NB4-R1 cells were stimulated by combining the action of RA and cAMP (Figure 2b) . A biphasic induction of JEM-1 mRNA was again observed with the same time-course as for NB4 cells in Figure 1b , c. Therefore, the up-regulation of JEM was correlated with cell maturation triggered by cAMP of RA-primed NB4 and NB4-R1 cells (see Figures 1 and 2) . Thus JEM upregulation seemed not to be a direct response to retinoids.
Although RA stimulation alone was not sufficient to upregulate JEM-1 in NB4-R1 cells, the number of JEM-1 transcripts, as detected on Northern blot, was comparatively higher than in untreated NB4 cells. To better quantify the relative levels of JEM-1 transcripts in NB4, NB4-R1 and NB4-R2 cells, we developed a quantitative PCR assay for the 3 kb JEM-1 transcript. An internal PCR amplification control obtained from a truncated JEM cDNA lacking the leucine domain (JEM⌬ ) was included in all PCR reactions at the same quantity (see Materials and methods). Both JEM-1 mRNA from cell extracts and JEM⌬ 179-206 cDNA were processed by RT-PCR using the same sense and antisense oligonucleotides, thus generating two distinct cDNA bands of 575 bp and 491 bp, respectively. Quantification of RNA loading in the PCR reaction was based on a parallel PCR amplification of actin cDNA. Figure 3a shows that the NB4, NB4-R1 and NB4-R2 cell lines greatly differed with respect to the basal levels of JEM-1 transcripts. For instance, while JEM-1 mRNA was very low or undetectable in NB4 cells (lane 1), it was indeed The time-course and levels of JEM-1 expression reported above suggest that JEM-1 is unlikely to be directly involved in the early events of RA-induced NB4 cell maturation. After 48 h of incubation with RA, JEM-1 still had not reached its peak of expression (see Figure 1a) , while morphological and biochemical features (not shown) already indicated that maturation had been triggered. Therefore, these results together with the data obtained from the induction of JEM-1 in NB4-R1 cells by ATRA plus cAMP (Figure 2b) , and the data from maturation induction of NB4 cells by LG268 plus cAMP (Figure 1c) , support the hypothesis that JEM-1 is probably a late marker of APL cell maturation or possibly a late effector 
JEM-1 mRNA expression patterns in APL bone marrow cells
We wanted to verify whether lower JEM-1 expression in NB4 cells was also encountered with leukemia cell samples from APL patients. Bone marrow cells from two APL patients were analyzed by PCR amplification with the protocol used for NB4 cells. Patients 1 and 2 expressed distinct levels of JEM-1 transcripts (Figure 3b ), respectively undetectable (similar to NB4 cells) and low (close to the basal level found in NB4-R2) when analyzed in the same condition of PCR amplification. These differences may well reflect the different numbers of leukemia cells in the biological sample, if normal non-leukemia cells expressed the JEM-1 transcript. Indeed, patients 1 and 2 bone marrow significantly differed with respect to translocation positive cells (FISH: 90% vs 75% positive cells; t(15;17): 100% vs 70%, in P1 and P2, respectively).
We examined whether the therapeutic action of RA in patient 1, whose JEM-1 mRNA was undetectable by PCR at diagnosis (Figure 3b 
Ubiquitous expression of JEM-1 in normal and tumour tissues
As we wanted to determine whether a low expression of JEM-1 is a specific feature of APL cells, we extended our study to other hemopoietic malignancies.
We first performed comparative Northern blot analysis of the expression of the 3 kb JEM-1 transcript in a series of leukemia cell lines. Table 1 clearly indicates that all erythroid leukemia-derived cell lines tested constitutively expressed high levels of the 3 kb JEM-1 transcript, while monocytic leukemia derived cell lines expressed low or undetectable levels of JEM mRNA. The situation in myeloid leukemia derived cell lines was less homogenous, with HL60 and NB4 cells expressing respectively little and undetectable amounts of JEM-1 transcripts, while in other cell lines JEM-1 was strongly expressed. All solid tumor-derived cell lines analyzed expressed variable but relatively high amounts of the 3 kb JEM-1 mRNA, and therefore no clear correlation with one of the classified pathologies has emerged (Table 2 ). However, this study points to those few cell lines with no or only little expression of JEM-1 and might prove interesting for further investigation. Altogether, the expression of JEM-1 appeared highly ubiquitous, with no tissue correlation suggestive of a particular function.
We extended our investigation on tissue expression of JEM-1, in a series of poly A + RNAs from normal adult or fetal human tissues. The results shown in Figure 4 clearly confirm Table 1 JEM-1 mRNA (3 kb) expression in leukemia-derived cell lines
Northern-blot hybridization signals obtained using a JEM-1 cDNA probes (see Methods) were standardized by using actin. A graded expression (from a indetectable signal (-) to a very strong signal (++++) was observed. that JEM-1 is a ubiquituously expressed gene. Interestingly, however, the profile of expression varied in that transcripts of various sizes were expressed in some tissues. The relative amounts of these distinct transcripts also varied. The 3 kb transcripts clearly appeared to be a common feature to all cell types, both adult and fetal, with the exception of peripheral blood leukocytes in which JEM-1 was not detected. In some hemopoietic organs such as spleen or thymus, JEM-1 expression was low compared to other organs like placenta, testis or heart. Moreover, in some tissues such as testis, transcripts of smaller size (2 kb) were also strongly expressed. A minor 4.4 kb transcript revealed with the JEM-1 probe was also detected in several tissues.
Conclusions
In this work, we have shown that the JEM-1 3 kb transcript showed little or no expression in NB4 cells and variable amounts were detected in the bone marrow cells of two APL patients tested. We also observed that the RA-sensitive cell line, NB4, and two RA-resistant subclones of NB4 cells expressed variable amounts of JEM-1 transcripts. In all cases where both NB4 cells and NB4-R1 cells were induced to granulocytic maturation, JEM-1 expression always showed a similar biphasic pattern. Retinoids which alone failed to trigger maturation, also failed to up-regulate JEM-1, despite the fact that these drugs could transcriptionally regulate other RAresponsive genes in these cells (CD18 integrin, c-Myc, RXR␣, PR3/myeloblastin genes, in Refs 19, 31 and unpublished data). When retinoids required the cooperation of cAMP to induce cell maturation, this cooperation was also required to up-regulate JEM-1. Altogether, these findings suggest that JEM-1 upregulation is associated with APL cell maturation, and the
Figure 4
Northern blot analysis of poly A + RNA from fetal and adult human tissue biopsies. Hybridization of the same blotted membranes (MultiTissues Blot, Clontech) with a ␤-actin probe gave roughly similar labeling, except for skeletal muscle, placenta and heart where ␤-actin was much higher.
time-course of induction of the transcript favors the hypothesis that it is involved at a late stage in this process.
The finding that the resistant subclones NB4-R1 and R2 expressed higher levels of JEM-1 might be in agreement with the hypothesis that these subclones selected under the selective pressure of RA 18, 19 are indeed more advanced in the maturation process than NB4 cells. Further investigations should indicate whether or not JEM-1 expression can be used as a marker for progression of APL cells towards terminal maturation.
Although JEM-1 is expressed in many human leukemia and tumor cell types, it was intriguing that the level of expression greatly varied (Tables 1 and 2 ). The level of expression among myeloid leukemia derived cell lines was heterogenous, while it was more constantly low and high, respectively, in monocytic and erythroid leukemia derived cell lines (Table 1) . Some cell lines, like NB4, HL60, U937 and THP1, expressed low or undetectable levels of JEM-1 transcripts, while K562 could be considered as a highly expressing cell line. Among normal hemopoietic cells, thymocytes and peripheral blood leukocytes expressed little or no JEM-1 transcripts (Figure 4 ). Based on total RNA analysis (Table 2) , we concluded that the 3 kb JEM-1 transcript is ubiquitously expressed in most cell lines derived from human solid tumors. Interestingly, amongst normal tissues, poly A + RNA analyses revealed that testis strongly expressed an additional shorter transcript recognized by the JEM-1 cDNA probe. In addition, a higher size 4.4 kb was also detected.
Further experiments should determine the molecular basis of the tissue variability in JEM-1 expression. These differences may not depend solely on gene transcription. Interestingly, JEM-1 cDNA encodes in its 3ЈUTR several AU-rich sequence elements (AUUUA) known to generate instability of the mRNAs of cytokine genes and proto-oncogenes. 46 In some cell types JEM-1 mRNA may be more susceptible to mRNA degradation. The elucidation of the genomic structure of JEM-1 (Fant et al, in preparation) should help to determine whether the 4.4 kb and 2 kb mRNAs are generated from the JEM-1 gene by alternative splicing, or correspond to transcripts from a parent gene showing significant sequence homologies.
Finally, an important task to elucidate the function of this gene will be to establish a correlation between JEM-1 mRNA expression and the amount of endogenous Jem-1 protein expressed in tissues. So far, a polyclonal antibody developed against the E. coli recombinant protein failed to identify the endogenous Jem-1 protein, while in contrast the ectopically expressed Jem-1 protein was detected (Ref. 44 and Tong et al, submitted). These data could be explained by hypothesizing that the Jem-1 protein is expressed at extremely low levels under physiological conditions, or that the protein has a short life span, due to active proteolytic degradation. In this respect, it is noteworthy that Jem-1 contains a PEST motif 44 associated with phosphorylation and glycosylation sites which may participate in degradation of the protein. 47 At this stage it remains difficult to offer a biological interpretation of the differing levels of JEM-1 transcripts found in tissues. However, the main conclusion emerging from this study is that JEM-1 is ubiquitously expressed in human tissues and that NB4 cells show strikingly weak expression of this gene. One salient point of this work remains the correlation between JEM-1 expression and APL cell maturation. It will be important to determine whether these features are related to the genetic defect of APL cells, or whether it reflects the differentiation stage at which leukemia promyelocytes are arrested.
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